The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. حسب Gui Araujo (22170819)

"…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. (D) As a result, the introduction of mutualistic interactions promotes a growth in complexity in communities where it was once established as low, while stopping the introduction of further mutualistic interactions causes a slight decrease in complexity. …"

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes حسب Shakkira Erimban (6882539)

الموضوعات:

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes حسب Shakkira Erimban (6882539)

الموضوعات:

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics. حسب Oscar F. C. van den Bosch (22184246)

الموضوعات:

Table 1_Effect of decreased suspended sediment content on chlorophyll-a in Dongting Lake, China.docx حسب Le Zhang (88249)

"…However, the effect of reduced SSC on Chl-a is poorly studied. Here, we compared and analyzed the distribution conditions of Chl-a in 6 representative years for both before the implementation of Three Gorges Dam (TGD) (BIT) and after the implementation of TGD (AIT), using the TM/OLI data and NIR-red inversion model. …"

The linearly decreasing convergence factor a. حسب Junhao Wei (6816803)

Predicting pattern diversity decreases as a function of and . حسب Selim Haj Ali (21222613)

"…(a) and (b): Average negative predictive value for and , respectively for and . …"

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات: